Alternate Names
Genome polyprotein, Capsid protein C, Capsid protein, Core protein, Protein prM, Precursor membrane protein, Peptide pr, Peptide precursor, Small envelope protein M, Matrix protein, Envelope protein E, Non-structural protein 1, NS1, Non-structural protein 2A, NS2A, Serine protease subunit NS2B, Flavivirin protease NS2B regulatory subunit, Non-structural protein 2B, Serine protease NS3, 3.4.21.91, 3.6.1.15, 3.6.4.13, Flavivirin protease NS3 catalytic subunit, Non-structural protein 3, Non-structural protein 4A, NS4A, Peptide 2k, Non-structural protein 4B, NS4B, RNA-directed RNA polymerase NS5, 2.1.1.56, 2.1.1.57, 2.7.7.48, NS5
Background
Zika virus (ZIKV) is anarthropod-borne flavivirustransmitted mainly byAedes aegyptiandAedes albopictusmosquitoes. Closely related to dengue and yellow fever viruses, ZIKV was first discovered in Uganda in 1947. While most infections cause mild fever, rash, and conjunctivitis, major outbreaks in the Americas revealed strong links toGuillain–Barré syndromein adults andcongenital Zika syndromein newborns, including microcephaly and other neurological defects.At the molecular level, ZIKV is apositive-sense single-stranded RNA virus, encoding both structural proteins (C, prM, E) and non-structural proteins (NS1–NS5). These viral proteins play central roles in viral replication, immune evasion, and host-pathogen interactions, making them key research targets. Two major lineages—African and Asian—have been identified, with the Asian lineage responsible for large-scale epidemics in the Pacific and the Americas.With no licensed vaccine or antiviral therapy available, ZIKV remains apriority in global virology and immunology research. abinScience supports scientists by providinghigh-quality ZIKV antibodies, recombinant proteins, and assay solutionsto accelerate discoveries in pathogenesis, diagnostics, and therapeutic development.